Cargando…

p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya

BACKGROUND: The identification of suited early detection tests is one among the multiple requirements to reduce cervical cancer incidence in developing countries. METHODS: We evaluated p16(INK4a)/Ki-67 dual-stain cytology in a screening population in Thika district, Kenya and compared it to high-ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngugi, Caroline Wangari, Schmidt, Dietmar, Wanyoro, Karanja, Boga, Hamadi, Wanzala, Peter, Muigai, Anne, Mbithi, John, von Knebel Doeberitz, Magnus, Reuschenbach, Miriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531480/
https://www.ncbi.nlm.nih.gov/pubmed/26265934
http://dx.doi.org/10.1186/s13027-015-0020-2
_version_ 1782385045115240448
author Ngugi, Caroline Wangari
Schmidt, Dietmar
Wanyoro, Karanja
Boga, Hamadi
Wanzala, Peter
Muigai, Anne
Mbithi, John
von Knebel Doeberitz, Magnus
Reuschenbach, Miriam
author_facet Ngugi, Caroline Wangari
Schmidt, Dietmar
Wanyoro, Karanja
Boga, Hamadi
Wanzala, Peter
Muigai, Anne
Mbithi, John
von Knebel Doeberitz, Magnus
Reuschenbach, Miriam
author_sort Ngugi, Caroline Wangari
collection PubMed
description BACKGROUND: The identification of suited early detection tests is one among the multiple requirements to reduce cervical cancer incidence in developing countries. METHODS: We evaluated p16(INK4a)/Ki-67 dual-stain cytology in a screening population in Thika district, Kenya and compared it to high-risk human papillomavirus (HR-HPV) DNA testing and visual inspection by acetic acid (VIA) and Lugol’s iodine (VILI). RESULTS: Valid results for all tests could be obtained in 477 women. 20.9 % (100/477) were tested positive for HR-HPV DNA, 3.1 % (15/477) had positive VIA/VILI and 8.2 % (39/477) positive p16(INK4a)/Ki-67 cytology. Of 22 women that showed up for colposcopy and biopsy, 6 women were diagnosed with CIN3 and two with CIN2. All women with CIN2/3 were negative in VIA/VILI screening and positive by HR-HPV DNA testing. But HPV was also positive in 91.7 % (11/12) of women with normal histology. p16(INK4a)/Ki-67 cytology was positive in all 6 women with CIN3, in one of the two CIN2 and in only 8.3 % (1/12) of women with normal histology. CONCLUSIONS: p16(INK4a)/Ki-67 cytology is an interesting test for further studies in developing countries, since our findings point to a lower fraction of false positive test results using p16(INK4a)/Ki-67 cytology compared to HPV DNA testing in a Kenyan screening population. VIA/VILI missed all histology-proven CIN2/3.
format Online
Article
Text
id pubmed-4531480
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45314802015-08-12 p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya Ngugi, Caroline Wangari Schmidt, Dietmar Wanyoro, Karanja Boga, Hamadi Wanzala, Peter Muigai, Anne Mbithi, John von Knebel Doeberitz, Magnus Reuschenbach, Miriam Infect Agent Cancer Research Article BACKGROUND: The identification of suited early detection tests is one among the multiple requirements to reduce cervical cancer incidence in developing countries. METHODS: We evaluated p16(INK4a)/Ki-67 dual-stain cytology in a screening population in Thika district, Kenya and compared it to high-risk human papillomavirus (HR-HPV) DNA testing and visual inspection by acetic acid (VIA) and Lugol’s iodine (VILI). RESULTS: Valid results for all tests could be obtained in 477 women. 20.9 % (100/477) were tested positive for HR-HPV DNA, 3.1 % (15/477) had positive VIA/VILI and 8.2 % (39/477) positive p16(INK4a)/Ki-67 cytology. Of 22 women that showed up for colposcopy and biopsy, 6 women were diagnosed with CIN3 and two with CIN2. All women with CIN2/3 were negative in VIA/VILI screening and positive by HR-HPV DNA testing. But HPV was also positive in 91.7 % (11/12) of women with normal histology. p16(INK4a)/Ki-67 cytology was positive in all 6 women with CIN3, in one of the two CIN2 and in only 8.3 % (1/12) of women with normal histology. CONCLUSIONS: p16(INK4a)/Ki-67 cytology is an interesting test for further studies in developing countries, since our findings point to a lower fraction of false positive test results using p16(INK4a)/Ki-67 cytology compared to HPV DNA testing in a Kenyan screening population. VIA/VILI missed all histology-proven CIN2/3. BioMed Central 2015-08-11 /pmc/articles/PMC4531480/ /pubmed/26265934 http://dx.doi.org/10.1186/s13027-015-0020-2 Text en © Ngugi et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ngugi, Caroline Wangari
Schmidt, Dietmar
Wanyoro, Karanja
Boga, Hamadi
Wanzala, Peter
Muigai, Anne
Mbithi, John
von Knebel Doeberitz, Magnus
Reuschenbach, Miriam
p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya
title p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya
title_full p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya
title_fullStr p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya
title_full_unstemmed p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya
title_short p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya
title_sort p16(ink4a)/ki-67 dual stain cytology for cervical cancer screening in thika district, kenya
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531480/
https://www.ncbi.nlm.nih.gov/pubmed/26265934
http://dx.doi.org/10.1186/s13027-015-0020-2
work_keys_str_mv AT ngugicarolinewangari p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya
AT schmidtdietmar p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya
AT wanyorokaranja p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya
AT bogahamadi p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya
AT wanzalapeter p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya
AT muigaianne p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya
AT mbithijohn p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya
AT vonknebeldoeberitzmagnus p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya
AT reuschenbachmiriam p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya